Last reviewed · How we verify
Delayed treatment
At a glance
| Generic name | Delayed treatment |
|---|---|
| Also known as | Methotrexate, Observation |
| Sponsor | Edward Averbukh |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PHASE3)
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial (PHASE3)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Early Surgical Intervention of Congenital Hemivertebra in Young Children (NA)
- Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
- Iadademstat + SBRT With Atezo in ES-SCLC (PHASE1)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Delayed treatment CI brief — competitive landscape report
- Delayed treatment updates RSS · CI watch RSS
- Edward Averbukh portfolio CI